BNP Paribas Financial Markets Makes New $1.13 Million Investment in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)

BNP Paribas Financial Markets acquired a new position in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 193,748 shares of the company’s stock, valued at approximately $1,130,000. BNP Paribas Financial Markets owned 0.34% of Olema Pharmaceuticals at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of the stock. Charles Schwab Investment Management Inc. raised its stake in shares of Olema Pharmaceuticals by 0.7% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 332,950 shares of the company’s stock valued at $1,941,000 after buying an additional 2,189 shares in the last quarter. Boothbay Fund Management LLC lifted its holdings in Olema Pharmaceuticals by 10.8% in the fourth quarter. Boothbay Fund Management LLC now owns 31,226 shares of the company’s stock valued at $182,000 after buying an additional 3,056 shares during the period. Virtus ETF Advisers LLC boosted its stake in Olema Pharmaceuticals by 43.1% in the fourth quarter. Virtus ETF Advisers LLC now owns 10,579 shares of the company’s stock valued at $62,000 after acquiring an additional 3,185 shares during the last quarter. SG Americas Securities LLC boosted its stake in Olema Pharmaceuticals by 33.8% during the 4th quarter. SG Americas Securities LLC now owns 17,475 shares of the company’s stock worth $102,000 after acquiring an additional 4,419 shares during the last quarter. Finally, KLP Kapitalforvaltning AS bought a new position in Olema Pharmaceuticals during the 4th quarter worth approximately $30,000. 91.78% of the stock is owned by institutional investors.

Olema Pharmaceuticals Trading Up 5.8%

OLMA opened at $5.08 on Wednesday. The company’s fifty day moving average price is $4.31 and its two-hundred day moving average price is $5.99. Olema Pharmaceuticals, Inc. has a 1-year low of $2.86 and a 1-year high of $16.62. The company has a market cap of $347.58 million, a price-to-earnings ratio of -2.32 and a beta of 2.03.

Olema Pharmaceuticals (NASDAQ:OLMA) last announced its earnings results on Tuesday, May 13th. The company reported ($0.36) EPS for the quarter, beating the consensus estimate of ($0.49) by $0.13. As a group, equities analysts forecast that Olema Pharmaceuticals, Inc. will post -2.33 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on OLMA. Oppenheimer lowered their price objective on shares of Olema Pharmaceuticals from $25.00 to $22.00 and set an “outperform” rating on the stock in a report on Wednesday, May 14th. JPMorgan Chase & Co. cut their price objective on shares of Olema Pharmaceuticals from $30.00 to $28.00 and set an “overweight” rating for the company in a report on Friday, March 28th. The Goldman Sachs Group cut their price objective on shares of Olema Pharmaceuticals from $20.00 to $18.00 and set a “buy” rating for the company in a report on Wednesday, May 14th. Finally, HC Wainwright reissued a “buy” rating and issued a $30.00 price objective on shares of Olema Pharmaceuticals in a report on Monday, April 28th.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.